Geographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7

Sci Rep. 2017 Jun 12;7(1):3049. doi: 10.1038/s41598-017-02955-y.

Abstract

Although mean efficacy of multivalent pneumococcus vaccines has been intensively studied, variance in vaccine efficacy (VE) has been overlooked. Different net individual protection across settings can be driven by environmental conditions, local serotype and clonal composition, as well as by socio-demographic and genetic host factors. Understanding efficacy variation has implications for population-level effectiveness and other eco-evolutionary feedbacks. Here I show that realized VE can vary across epidemiological settings, by applying a multi-site-one-model approach to data post-vaccination. I analyse serotype prevalence dynamics following PCV7, in asymptomatic carriage in children attending day care in Portugal, Norway, France, Greece, Hungary and Hong-Kong. Model fitting to each dataset provides site-specific estimates for vaccine efficacy against acquisition, and pneumococcal transmission parameters. According to this model, variable serotype replacement across sites can be explained through variable PCV7 efficacy, ranging from 40% in Norway to 10% in Hong-Kong. While the details of how this effect is achieved remain to be determined, here I report three factors negatively associated with the VE readout, including initial prevalence of serotype 19F, daily mean temperature, and the Gini index. The study warrants more attention on local modulators of vaccine performance and calls for predictive frameworks within and across populations.

MeSH terms

  • Algorithms
  • Child
  • Child Day Care Centers / statistics & numerical data*
  • France / epidemiology
  • Greece / epidemiology
  • Heptavalent Pneumococcal Conjugate Vaccine / immunology
  • Heptavalent Pneumococcal Conjugate Vaccine / therapeutic use*
  • Hong Kong / epidemiology
  • Humans
  • Hungary / epidemiology
  • Models, Theoretical
  • Norway / epidemiology
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / microbiology
  • Pneumococcal Infections / prevention & control*
  • Portugal / epidemiology
  • Prevalence
  • Serogroup
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / immunology
  • Treatment Outcome

Substances

  • Heptavalent Pneumococcal Conjugate Vaccine